1. Detecting and Treating Asparaginase-Related Toxicities in Acute Lymphoblastic Leukemia

3. Activity Goals

4. Acute Lymphoblastic Leukemia (ALL)

5. Outcome: Adults vs Childhood ALL

6. PEG-asparaginase for Pediatric Patients

7. Retrospective Comparison of Adult vs Pediatric Protocols

8. Comparison of Adverse Events During Induction

9. Serum Asparaginase Concentrations

10. Grades 2-4 PEG-asparaginase-Related Adverse Events in Adults

12. PEG-asparaginase in Modified Pediatric Protocol

13. PK of Dex and Asparaginase Activity

14. Asparaginase Formulations and Half-life

15. PEGylated Asparaginase

16. Asparaginase

17. Current Dosing of Asparaginase

18. AEs From PEG-asparaginase From the CCG-Augmented Pediatric BFM Protocol

19. Asparaginase Hypersensitivity

20. AEs to PEG-asparaginase in Adults

21. Thrombosis

22. Antibodies to PEG-asparaginase

23. Measuring Asparaginase Activity

24. Monitoring Serum Asparaginase Activity

25. Dosing Asparaginase based on Serum Levels

26. Presence of Neutralizing Antibody: Switch to Erwinia Asparaginase

27. Why Use Asparaginase?

28. Using Pediatric-inspired Approaches in Adult ALL

29. The Importance of Asparaginase for ALL

30. Management of Asparaginase Toxicity in Adults

31. Conclusions

32. Abbreviations

33. Abbreviations (cont)

34. References

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)

43. References (cont)